Pfizer paying out millions, again, to settle off-label promotion charges in the US
This article was originally published in SRA
Once again, US pharma giant Pfizer is having to pay out millions of dollars to the US federal government and states to settle charges of illegal promotion of the company's medicines, with the latest settlements totaling about $98 million1. While a far cry from the $2.3 billion the New York drug maker paid under a 2009 guilty plea for promoting its cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug Bextra (valdecoxib), this is still a tidy sum of cash2.
You may also be interested in...
FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices.
Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.